The Lupus Research Alliance (LRA) is the world’s largest and most influential private funder of innovative lupus research. The LRA has committed more than $200 million for lupus research programs, issued 500+ grants and is partnering on more than one dozen clinical trials.

100 percent of all donations to the LRA go directly to support lupus research programs. Its Board of Directors cover all administrative and fundraising costs to ensure all money goes towards research.

The LRA collaborates with scientific and advocacy organizations as well as pharmaceutical companies and government agencies including the Foundation for the National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases, and the U.S. Department of Defense.

Guided by a world-class Scientific Advisory Board and Research Committee of the Board, the organization’s full spectrum of research includes fundamental, translational and clinical study.

The LRA continues to lead the field in supporting nearly every pivotal breakthrough that is improving treatment while advancing toward a cure.

After decades of groundbreaking research, new tools and technologies are now available to advance personalized medicine. The LRA can now drive research to understand how lupus works in each person – to develop cures and treatments that work for every individual.

The LRA established Lupus Therapeutics (LT) in 2018 to accelerate clinical trial development in lupus. LT is a wholly-owned subsidiary of LRA that serves as its clinical trial arm.

LT formed and oversees the first and only Lupus Clinical Investigators Network, comprised of clinician scientists from 57 of the most reputable academic medical centers in North America.

In just two years of opening its doors, 13 clinical trials are in various stages.

Visit LupusResearch.org to learn about the Lupus Research Alliance and how together we are breaking through.